[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596440":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":30,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Laboratoires RIVADIS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Rivadouce Group",null,"Patients aged 18 years and older, at risk of developing pressure ulcers (Braden Scale \\\u003C18), without existing ulcers at baseline, and for whom RIVADOUCE VEGETABLE SKINCARE OIL is applied via effleurage as part of routine clinical practice. Patients are followed for 35 ± 5 days to monitor the incidence of pressure ulcers and adverse events.",[13],{"name":14,"affiliation":15,"role":16},"Sylvie MEAUME, PhD","Hôpital Rotschild","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Renaud Urbinelli","CONTACT","+33658687286","etudes@clin-experts.fr",[24],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Multiples facilities","RECRUITING","Multiple Locations","France","FR",{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100596440","prevention-of-pressure-ulcers-by-effleurage-with-rivadouce-vegetable-skincare-oil-in-patients-at-risk-of-pressure-ulcers-100596440",false,"NCT07045480","Prevention of Pressure Ulcers by Effleurage With RIVADOUCE VEGETABLE SKINCARE OIL in Patients at Risk of Pressure Ulcers","Prevention of Pressure Ulcers by Effleurage With RIVADOUCE VEGETABLE SKINCARE OIL in Patients at Risk of Pressure Ulcers: Observational Study","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of inclusion.\n* At risk of developing pressure ulcers, as determined by clinical judgment and a Braden Scale score \\\u003C18.\n* No existing pressure ulcer at the time of inclusion.\n* Informed consent signed by the patient, or by a trusted third party or legal representative (for protected adults), after being informed about the study.\n* Expected length of stay ≥ 35 days ±5 days in the participating facility.\n* Planned use of RIVADOUCE VEGETABLE SKINCARE OIL on one or more pressure-prone areas as part of the facility's standard pressure ulcer prevention protocol.\n\nExclusion Criteria:\n\n* Use or planned use of multilayer dressings on the pressure-prone areas to be treated with the study product.\n* End-of-life patients, defined as having an estimated life expectancy of less than 3 months.\n* Patients who are not covered by social health insurance.","ALL","18 Years",{"count":42,"type":43},252,"ESTIMATED","OBSERVATIONAL","This is a prospective, non-interventional, multicenter, post-market clinical follow-up (PMCF) study conducted in real-life conditions to assess the clinical performance and safety of RIVADOUCE VEGETABLE SKINCARE OIL in the prevention of pressure ulcers (PUs) in at-risk adult patients. The product is intended to be applied through effleurage (gentle manual application without pressure) to pressure-prone skin areas as part of standard pressure ulcer prevention protocols.\n\nA total of 252 adult patients, with a Braden Scale score \\\u003C18 and no existing pressure ulcers at baseline, will be included across 10 to 20 French healthcare centers (e.g., rehabilitation units, long-term care facilities, or nursing homes). Participants will be followed for 35 ± 5 days.\n\nThe primary endpoint is the proportion of patients developing at least one stage 1 or higher pressure ulcer (per NPUAP 2014\u002F2019 classification) on treated areas (e.g., sacrum, heels, ischial and trochanteric regions). Secondary endpoints include the time to onset, progression of any developed ulcers, adverse events (AEs), device-related adverse events, and product usage compliance.\n\nThis PMCF study is required for the renewal of CE certification under the EU Medical Device Regulation (MDR) 2017\u002F745, and is designed according to ISO 14155:2020 standards. The study will provide updated clinical evidence on the device's safety and performance within its intended use.",[47],"Pressure Ulcer Prevention",[49,50,51,52,53],"Effleurage","Pressure Ulcer","Topical Emollient","Post-Market Clinical Follow-Up","Rivadouce","2025-06-23",{"date":56,"type":57},"2025-07-01","ACTUAL",{"date":59,"type":57},"2025-04-04",{"date":61,"type":43},"2026-01-31",{"name":5,"class":6},1]